This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by El-Zein, R. A. Articles by Spitz, M. R. Search for Related Content PubMed PubMed Citation Articles by El-Zein, R. A. Articles by Spitz, M. R.

Cytokinesis-Blocked Micronucleus Assay as a Novel Biomarker for Lung Cancer Risk

Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Randa A. El-Zein, Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Unit 1340, P.O. Box 301439, Houston, TX 77030-1439. Phone: 713-745-2539; Fax: 713-792-9568; E-mail: relzein{at}mdanderson.org.

In this case-control study, we modified the cytokinesis-block micronucleus (CBMN) assay, an established biomarker for genomic instability, to evaluate susceptibility to the nicotine-derived nitrosamine 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by measuring the frequency of NNK-induced chromosomal damage endpoints (micronuclei, nucleoplasmic bridges, and nuclear buds) per 1,000 binucleated lymphocytes. Spontaneous and NNK-induced chromosomal damage were significantly higher in lung cancer patients compared with controls. Forty-seven percent of cases (versus 12% of controls) had 4 spontaneous micronuclei, 66% of cases (and no controls) had 4 spontaneous nucleoplasmic bridges, and 25% of cases (versus 5% of controls) had 1 spontaneous nuclear bud (P < 0.001). Similarly, 40% of cases (versus 6% of the controls) had 5 NNK-induced micronuclei, 89% of cases (and no controls) had 6 induced nucleoplasmic bridges, and 23% of cases (versus 2% of controls) had 2 induced nuclear buds (P < 0.001). When analyzed on a continuous scale, spontaneous micronuclei, nucleoplasmic bridges, and nuclear buds were associated with 2-, 29-, and 6-fold increases in cancer risk, respectively. Similarly, NNK-induced risks were 2.3-, 45.5-, and 10-fold, respectively. We evaluated the use of CBMN assay to predict cancer risk based on the numbers of micronuclei, nucleoplasmic bridges, and nuclear buds defined by percentile cut points in controls. Probabilities of being a cancer patient were 96%, 98%, and 100% when using the 95th percentiles of spontaneous and NNK-induced micronuclei, nucleoplasmic bridges, and nuclear buds, respectively. Our study indicates that the CBMN assay is extremely sensitive to NNK-induced genetic damage and may serve as a strong predictor of lung cancer risk. (Cancer Res 2006; 66(12): 6449-56)

This article has been cited by other articles:

				R. A. El-Zein, M. Fenech, M. S. Lopez, M. R. Spitz, and C. J. Etzel Cytokinesis-Blocked Micronucleus Cytome Assay Biomarkers Identify Lung Cancer Cases Amongst Smokers Cancer Epidemiol. Biomarkers Prev., May 1, 2008; 17(5): 1111 - 1119. [Abstract] [Full Text] [PDF]

				B. Benassi, R. LeLeu, T. Bird, P. Clifton, and M. Fenech Cytokinesis-Block Micronucleus Cytome Assays for the Determination of Genotoxicity and Cytotoxicity of Cecal Water in Rats and Fecal Water in Humans Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2676 - 2680. [Abstract] [Full Text] [PDF]

				A. Zijno, F. Saini, and R. Crebelli Suitability of cryopreserved isolated lymphocytes for the analysis of micronuclei with the cytokinesis-block method Mutagenesis, September 1, 2007; 22(5): 311 - 315. [Abstract] [Full Text] [PDF]